| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2003.11.136 |
| P698 | PubMed publication ID | 12860938 |
| P50 | author | Nicholas J. Vogelzang | Q7025647 |
| P2093 | author name string | Clet Niyikiza | |
| Michael Boyer | |||
| Christian Manegold | |||
| Ulrich Gatzemeier | |||
| Claude Denham | |||
| E Kaukel | |||
| James J Rusthoven | |||
| James Symanowski | |||
| Paolo Paoletti | |||
| Pierre Ruffie | |||
| Salih Emri | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| cisplatin | Q412415 | ||
| P304 | page(s) | 2636-2644 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma | |
| P478 | volume | 21 |
| Q42598966 | 2012 Annual Meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines |
| Q47425620 | 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma. |
| Q30474771 | A 26-year-old male with mesothelioma due to asbestos exposure |
| Q90365685 | A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication |
| Q93369091 | A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma |
| Q35993489 | A P425R mutation of the proton-coupled folate transporter causing hereditary folate malabsorption produces a highly selective alteration in folate binding |
| Q37296603 | A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307 |
| Q90207142 | A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer |
| Q54046740 | A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. |
| Q53003365 | A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. |
| Q35028791 | A case of advanced malignant pleural mesothelioma treatment with chemotherapy and photodynamic therapy |
| Q36983993 | A case of mesothelioma masquerading pre-operatively as ovarian cancer and brief review of the literature |
| Q38760623 | A catalogue of treatment and technologies for malignant pleural mesothelioma |
| Q35855798 | A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. |
| Q54521295 | A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. |
| Q46170767 | A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma |
| Q36853747 | A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition |
| Q33789669 | A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer |
| Q37703404 | A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma. |
| Q92326343 | A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial |
| Q30588623 | A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial |
| Q51643878 | A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index. |
| Q33778076 | A new standard for malignant pleural mesothelioma |
| Q40340826 | A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report |
| Q40522944 | A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. |
| Q46561710 | A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma |
| Q85158783 | A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer |
| Q33397590 | A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer |
| Q36166846 | A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours |
| Q28200350 | A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours |
| Q58088398 | A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors |
| Q46472676 | A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors |
| Q33523445 | A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions |
| Q34300117 | A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients |
| Q43266878 | A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology |
| Q33397929 | A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer |
| Q33414357 | A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma |
| Q33367733 | A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer |
| Q33812537 | A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma |
| Q37364652 | A possible association between aprotinin and improved survival after radical surgery for mesothelioma |
| Q41846143 | A potential therapeutic strategy for malignant mesothelioma with gene medicine |
| Q64973042 | A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy. |
| Q34458042 | A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer |
| Q49901146 | A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma |
| Q36662001 | A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma |
| Q35190713 | A randomised controlled trial of intravenous zoledronic acid in malignant pleural disease: a proof of principle pilot study |
| Q59132458 | A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205) |
| Q47685374 | A review of bevacizumab in the treatment of malignant pleural mesothelioma |
| Q34278435 | A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice |
| Q42599445 | A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report |
| Q90326617 | A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial |
| Q38728079 | A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1. |
| Q64898547 | AMPK activation induced in pemetrexed-treated cells is associated with development of drug resistance independently of target enzyme expression. |
| Q46115026 | Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients |
| Q36948470 | Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma |
| Q36727434 | Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial |
| Q33418536 | Acute and fatal thrombocytopenic thrombotic purpura after a single dose of pemetrexed |
| Q54549098 | Adiponectin pathway attenuates malignant mesothelioma cell growth. |
| Q46869030 | Adjusting for observational secondary treatments in estimating the effects of randomized treatments |
| Q42127606 | Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma |
| Q85609708 | Advanced diffuse malignant peritoneal mesothelioma responding to palliative chemotherapy |
| Q28085551 | Advances in anticancer immunotoxin therapy |
| Q35832903 | Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach |
| Q64889484 | Advances in pulmonary and pleural malignant disorders. |
| Q47912434 | Advances in systemic therapy for malignant mesothelioma: future perspectives |
| Q36162505 | Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma |
| Q26787294 | Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma |
| Q38153818 | Advances in the management of pleural disease. |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q38800916 | Advances in treatment of mesothelioma. |
| Q34340354 | Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. |
| Q36523494 | Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature |
| Q37507415 | An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. |
| Q33813008 | An epigenetic mechanism for capecitabine resistance in mesothelioma |
| Q36327104 | An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer |
| Q52659191 | An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs). |
| Q28603645 | An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol |
| Q34692326 | An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity. |
| Q35182037 | Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). |
| Q53230721 | Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets. |
| Q64927500 | Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos. |
| Q39148274 | Anti-CTLA-4 therapy for malignant mesothelioma |
| Q38004067 | Anti-angiogenic therapies for malignant pleural mesothelioma |
| Q90056612 | Antiangiogeneic Strategies in Mesothelioma |
| Q33530405 | Antimetabolites and cancer: emerging data with a focus on antifolates |
| Q35989821 | Antimetabolites in the management of non-small cell lung cancer |
| Q50864512 | Antimetabolites in the treatment of advanced pleural mesothelioma: a network meta-analysis of randomized clinical trials. |
| Q43239330 | Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo |
| Q38764836 | Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model. |
| Q33898584 | Apoptosis by [Pt(O,O'-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma |
| Q33999822 | Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma |
| Q36027639 | Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? |
| Q39662661 | Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells. |
| Q51428846 | Asbestos and the lung in the 21st century: an update. |
| Q38018217 | Asbestos-related pleuropulmonary diseases: benign and malignant |
| Q30837515 | Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials |
| Q92492646 | Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics |
| Q33623718 | Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum |
| Q38085569 | Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases |
| Q47162696 | Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells |
| Q51980244 | Automated matching of temporally sequential CT sections. |
| Q28533736 | BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma |
| Q57983113 | BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state |
| Q27851697 | BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. |
| Q30478994 | BTS statement on malignant mesothelioma in the UK, 2007. |
| Q31166420 | Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data with Applications to Cancer Clinical Trials |
| Q41008161 | Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial |
| Q64069657 | Bilateral diffuse pulmonary infiltrates secondary to malignant peritoneal mesothelioma - A rare clinical presentation |
| Q60928995 | Biodistribution and Tumor Uptake of Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft |
| Q28387194 | Biomarkers and prognostic factors for mesothelioma |
| Q37335377 | Biomarkers for malignant pleural mesothelioma: current status |
| Q55053946 | Biomarkers in malignant mesothelioma-an unfulfilled need or a waste of resources? |
| Q41082952 | Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor |
| Q92460981 | Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life |
| Q57476476 | Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis |
| Q92906702 | Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression |
| Q52590080 | CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients. |
| Q52579899 | CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. |
| Q34302855 | CREB-induced inflammation is important for malignant mesothelioma growth |
| Q47307668 | CTLA-4 blockade in mesothelioma: ineffective or reason for optimism? |
| Q38252348 | CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? |
| Q56896147 | CTLA4 blockade in patients with malignant mesothelioma |
| Q37451193 | Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed |
| Q59793523 | Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway |
| Q38709260 | Calycosin Enhances Some Chemotherapeutic Drugs Inhibition of Akt Signaling Pathway in Gastric Cells |
| Q42588769 | Cancer chemotherapy: targeting folic acid synthesis |
| Q38786054 | Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. |
| Q35057364 | Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium |
| Q39528131 | Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin |
| Q38119922 | Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. |
| Q46971325 | Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma. |
| Q37575602 | Changing the clinical picture of challenging tumors: tales becoming reality? |
| Q64235291 | Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP) |
| Q35275675 | Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions |
| Q34353359 | Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma |
| Q40005366 | Characterization of human mesothelioma cell lines as tumor models for suicide gene therapy |
| Q36295004 | Checkpoint Blockade in Lung Cancer and Mesothelioma |
| Q91123969 | Checkpoint inhibitors in mesothelioma: hope for the future? |
| Q61051793 | Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma |
| Q38155856 | Chemotherapy advances in small-cell lung cancer |
| Q35141369 | Chemotherapy and targeted therapies for unresectable malignant mesothelioma |
| Q52853807 | Chemotherapy for Advanced Non-small Cell Lung Cancer. |
| Q81295701 | Chemotherapy for malignant pleural mesothelioma |
| Q83789589 | Chemotherapy for malignant pleural mesothelioma |
| Q37090808 | Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future |
| Q43183112 | Chemotherapy maintenance: an option for prolonged survival in malignant peritoneal mesothelioma? |
| Q86113339 | Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens |
| Q36022779 | Chemotherapy options and new advances in malignant pleural mesothelioma |
| Q90612192 | Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma |
| Q52672893 | Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. |
| Q33217865 | Chemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment |
| Q53251663 | Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. |
| Q47133994 | Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. |
| Q37594406 | Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma |
| Q29248725 | Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma |
| Q53879306 | Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM). |
| Q36755228 | Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma |
| Q34957369 | Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma |
| Q37328494 | Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck |
| Q34411569 | Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma |
| Q36429607 | Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent |
| Q35542880 | Clinical characteristics and treatment outcomes in 132 patients with malignant mesothelioma |
| Q51578818 | Clinical investigation of malignant mesothelioma in Japan. |
| Q37624021 | Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma. |
| Q47133971 | Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. |
| Q42139851 | Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma |
| Q38909086 | Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. |
| Q36723787 | Clinical significance of serum CA125 in diffuse malignant mesothelioma |
| Q41149227 | Clinical targeting recombinant immunotoxins for cancer therapy |
| Q36285607 | Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma |
| Q46787186 | Clinical, histologic, and genetic features of mesothelioma in a 7-year-old child |
| Q33577805 | Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma |
| Q39963783 | Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. |
| Q57138329 | Combination immune checkpoint blockade as an effective therapy for mesothelioma |
| Q34627854 | Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis |
| Q37679984 | Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma |
| Q59137556 | Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations |
| Q99604609 | Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells |
| Q58804834 | Combining immunotherapy with radiation therapy in thoracic oncology |
| Q42585952 | Comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'. |
| Q36985910 | Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation |
| Q40336711 | Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma |
| Q33418020 | Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute |
| Q89823102 | Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos |
| Q34124614 | Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus |
| Q34493719 | Computerized segmentation and measurement of malignant pleural mesothelioma |
| Q52714599 | Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model. |
| Q37029331 | Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma |
| Q90191898 | Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review |
| Q59132464 | Current chemotherapy strategies in malignant pleural mesothelioma |
| Q37086026 | Current concepts in malignant pleural mesothelioma. |
| Q89881656 | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
| Q37817035 | Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment |
| Q28393560 | Current issues in malignant pleural mesothelioma evaluation and management |
| Q38641574 | Current surgical strategies for malignant pleural mesothelioma |
| Q38161735 | Current therapeutic strategies and novel approaches in osteosarcoma |
| Q37232309 | Current therapies for malignant pleural mesothelioma |
| Q35146940 | Customizing systemic therapy in patients with advanced non-small cell lung cancer |
| Q89598588 | Cyclin-Dependent Kinase and Antioxidant Gene Expression in Cancers with Poor Therapeutic Response |
| Q64899643 | Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. |
| Q51308431 | Deciduoid mesothelioma: cytologic presentation and diagnostic pitfalls. |
| Q92167575 | Deep convolutional neural networks for the automated segmentation of malignant pleural mesothelioma on computed tomography scans |
| Q89521341 | Deep learning-based segmentation of malignant pleural mesothelioma tumor on computed tomography scans: application to scans demonstrating pleural effusion |
| Q35789268 | Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development |
| Q39392511 | Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells. |
| Q38059514 | Dendritic cell-based immunotherapy in mesothelioma |
| Q24635465 | Depressogenic effects of medications: a review |
| Q37400550 | Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity |
| Q35639774 | Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis |
| Q35646297 | Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies. |
| Q36821113 | Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies |
| Q30371725 | Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. |
| Q39012195 | Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis |
| Q37612152 | Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. |
| Q46032752 | Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma. |
| Q37833952 | Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research |
| Q91809371 | Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity |
| Q36140968 | Distinctive clinical characteristics of malignant mesothelioma in young patients. |
| Q37090784 | Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database |
| Q47974790 | Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study |
| Q99582688 | Does size matter? -a population-based analysis of malignant pleural mesothelioma |
| Q42366634 | Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. |
| Q41339198 | Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed |
| Q33266936 | Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report |
| Q92530064 | Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma |
| Q37845248 | Drug therapy of cancer |
| Q90647308 | Dual-input tracer kinetic modeling of dynamic contrast-enhanced MRI in thoracic malignancies |
| Q40565147 | Duodenal perforation in a patient with non-small cell lung cancer receiving Pemetrexed-Cisplatin combination |
| Q57177411 | Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study |
| Q64094089 | Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria |
| Q50973584 | E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells. |
| Q36493568 | ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms |
| Q93106182 | EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma |
| Q83206656 | Early mesothelioma revisited |
| Q58765920 | Early-stage Clinical Characterization of Malignant Pleural Mesothelioma |
| Q37105343 | Effect of folic acid and vitamin B12 on pemetrexed antifolate chemotherapy in nutrient lung cancer cells |
| Q33432955 | Effect of renal function on pemetrexed-induced haematotoxicity |
| Q88875732 | Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma |
| Q84780390 | Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma |
| Q33427414 | Efficacies and adverse reactions of modified vitamin supplement programs before pemetrexed chemotherapy as a second-line treatment against epidermal growth factor receptor (EGFR) mutant wild-type lung adenocarcinoma |
| Q64285361 | Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial |
| Q43686149 | Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial |
| Q40163076 | Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. |
| Q53214981 | Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. |
| Q51807221 | Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. |
| Q36019729 | Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell |
| Q38968761 | Efficacy of piroxicam plus cisplatin-loaded PLGA nanoparticles in inducing apoptosis in mesothelioma cells |
| Q58128443 | Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer |
| Q90748160 | Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading? |
| Q36758593 | Emerging drugs for mesothelioma |
| Q35015611 | Emerging role of pemetrexed in ovarian cancer |
| Q37645201 | Emerging treatment options in the management of non-small cell lung cancer. |
| Q90613926 | Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma |
| Q34747922 | EphB4 as a therapeutic target in mesothelioma |
| Q35827405 | Epidemiology of mesothelioma in Egypt. A ten-year (1998-2007) multicentre study. |
| Q54538613 | Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. |
| Q46548604 | Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma |
| Q34072810 | Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. |
| Q60954580 | Establishment and characterization of CRISPR/Cas9-mediated NF2 human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma |
| Q35093873 | Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek University Pulmonary Department |
| Q43724326 | Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment |
| Q48060347 | Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care |
| Q37406496 | Estimation of pulmonary motion in healthy subjects and patients with intrathoracic tumors using 3D-dynamic MRI: initial results |
| Q90297408 | Evaluation of Light Fluence Distribution Using an IR Navigation System for HPPH-mediated Pleural Photodynamic Therapy (pPDT) |
| Q38945140 | Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesothelioma†. |
| Q41340663 | Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma |
| Q46612586 | Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group |
| Q45928394 | Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. |
| Q47127588 | Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions |
| Q37686318 | Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease |
| Q37214250 | Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma |
| Q61709331 | Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom |
| Q47096401 | Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study |
| Q92439627 | Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status |
| Q39236993 | Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma |
| Q42335278 | Expression and therapeutic significance of estrogen receptor β in malignant pleural mesothelioma |
| Q47948817 | Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma |
| Q39298123 | Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma. |
| Q38437441 | Expression of bcl-2 family members in malignant pleural mesothelioma |
| Q39933225 | Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis |
| Q40483522 | Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years. |
| Q47759752 | Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach |
| Q35782796 | Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients |
| Q41847770 | FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma |
| Q89017219 | FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients |
| Q51617036 | FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. |
| Q35678085 | Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales |
| Q44610633 | Factors influencing long-term survival in mesothelioma patients--results of the German mesothelioma register |
| Q43128653 | Feasibility study of dose-dense biweekly administered pemetrexed in patients with non-small cell lung cancer. |
| Q35751860 | Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors |
| Q50850318 | Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury. |
| Q38959812 | Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. |
| Q28389185 | Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma |
| Q24628879 | Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma |
| Q34679620 | Fine-Needle Aspiration Biopsies for Gene Expression Ratio-Based Diagnostic and Prognostic Tests in Malignant Pleural Mesothelioma |
| Q35832320 | First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. |
| Q47868774 | First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma |
| Q37449024 | First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype |
| Q39018529 | Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1). |
| Q36821171 | Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma |
| Q34669260 | Fool's gold, lost treasures, and the randomized clinical trial |
| Q55221451 | Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. |
| Q37180702 | Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma |
| Q36354734 | From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates |
| Q38870857 | Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q33690709 | GAS5 long non-coding RNA in malignant pleural mesothelioma. |
| Q37243005 | Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810) |
| Q54698040 | Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. |
| Q33378691 | Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma |
| Q37052430 | Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study |
| Q28384371 | Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma |
| Q38079969 | Gene therapy for malignant mesothelioma: current prospects and challenges |
| Q48294725 | Generalized eczema craquelé (asteatotic dermatitis) associated with pemetrexed treatment. |
| Q33899105 | Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro |
| Q35699080 | Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma |
| Q40176023 | Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. |
| Q38555471 | Glucocorticoids and Cancer. |
| Q28394028 | Guidelines for the diagnosis and treatment of malignant pleural mesothelioma |
| Q48292976 | HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. |
| Q33645607 | Harnessing the potential synergy of combining radiation therapy and immunotherapy for thoracic malignancies |
| Q48394328 | Health-related quality of life and inflammatory markers in malignant pleural mesothelioma |
| Q55311618 | Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity. |
| Q26799894 | Hedgehog Signaling in Malignant Pleural Mesothelioma |
| Q41262195 | Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Toxicity and outcomes at an Australian institution |
| Q55481165 | Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. |
| Q88924373 | Heterogeneity in Malignant Pleural Mesothelioma |
| Q37662700 | Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials |
| Q90198734 | How I treat malignant pleural mesothelioma |
| Q36259724 | Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. |
| Q40421611 | Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth |
| Q62392158 | Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma |
| Q34241413 | Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter |
| Q89457615 | Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma |
| Q98735838 | Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients |
| Q103740398 | Identification of the prognostic and immunotherapeutic potential of L antigen family member 3 in malignant pleural mesothelioma |
| Q36862865 | Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN). |
| Q35649214 | Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. |
| Q38717244 | Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? |
| Q38212149 | Immune therapies for malignant mesothelioma |
| Q38022807 | Immunotherapies for non-small-cell lung cancer and mesothelioma. |
| Q33645613 | Immunotherapy and radiation therapy for malignant pleural mesothelioma. |
| Q38180749 | Immunotherapy for malignant pleural mesothelioma. Current status and future prospects |
| Q33890551 | Immunotherapy for malignant pleural mesothelioma: current status and future directions |
| Q90612209 | Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives |
| Q38390104 | Immunotherapy prospects in the treatment of lung cancer and mesothelioma |
| Q90782085 | Immunotherapy trials in mesothelioma - promising results, but don't stop here |
| Q39728506 | Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma |
| Q96131716 | Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds |
| Q33877584 | Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. |
| Q36322368 | Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients |
| Q85364510 | In Reply |
| Q52559185 | In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM). |
| Q90383407 | In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes |
| Q36180331 | In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma |
| Q80396496 | In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression |
| Q33890506 | In vitro experimental models of mesothelioma revisited |
| Q33665367 | In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells |
| Q37880216 | Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation |
| Q39769492 | Incidence of interstitial lung disease in patients with mesothelioma in the west part of Japan |
| Q60395357 | Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma |
| Q39818881 | Individualizing Mesothelioma Treatment: Small Steps Into a Brighter Future |
| Q53990140 | Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. |
| Q39350596 | Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma |
| Q33400437 | Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals |
| Q34616107 | Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. |
| Q37090789 | Inflammation in malignant mesothelioma - friend or foe? |
| Q49835562 | Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma |
| Q93039466 | Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy |
| Q90167838 | Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism |
| Q37457703 | Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. |
| Q36557343 | Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells |
| Q94552713 | Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin |
| Q42369564 | Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1. |
| Q38429562 | Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma. |
| Q51416101 | Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. |
| Q55088639 | Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. |
| Q57153508 | Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma |
| Q34974037 | Interferon-β produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells |
| Q53586030 | Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy. |
| Q91949972 | Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma |
| Q38221769 | Interventional therapies for malignant pleural effusions: the present and the future. |
| Q38849618 | Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells. |
| Q39438165 | Intraoperative adjuncts for malignant pleural mesothelioma |
| Q34293068 | Investigational approaches for mesothelioma |
| Q91123540 | Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial |
| Q38647275 | Is immunotherapy a viable option in treating mesothelioma? |
| Q88913091 | Is there a role for immunotherapy in malignant pleural mesothelioma? |
| Q59137560 | Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma? |
| Q36063077 | Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial |
| Q35540770 | Joint modeling of multiple longitudinal patient-reported outcomes and survival |
| Q44173242 | Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. |
| Q39043614 | LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade |
| Q36490313 | Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells |
| Q49232092 | Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. |
| Q37629910 | Late cutaneous metastases to the face from malignant pleural mesothelioma: a case report and review of the literature |
| Q28395597 | Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies |
| Q93048382 | Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives |
| Q38255347 | Local and systemic therapies for malignant pleural mesothelioma |
| Q57452854 | Local cancer recurrence: The realities, challenges, and opportunities for new therapies |
| Q81608122 | Localized malignant mesothelioma in the middle mediastinum: report of a case |
| Q34970431 | Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM). |
| Q36417109 | Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy |
| Q26849259 | Looking up: Recent advances in understanding and treating peritoneal carcinomatosis |
| Q47653923 | Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells |
| Q85640217 | Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P |
| Q64907367 | Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. |
| Q81086287 | Lung cancer |
| Q36328370 | Lung cancer: Biology and treatment options |
| Q83464539 | Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy |
| Q31019143 | MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data |
| Q27853125 | MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. |
| Q92653196 | MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma |
| Q34182679 | MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma |
| Q46414310 | MVP and vinorelbine for malignant pleural mesothelioma |
| Q34616102 | Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. |
| Q43274035 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study |
| Q58386415 | Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression |
| Q39470931 | Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab |
| Q87849396 | Malignant Mesothelioma of the Tunica Vaginalis Testis: Outcomes Following Surgical Management Beyond Radical Orchiectomy |
| Q39366003 | Malignant Mesothelioma: Time to Translate? |
| Q35623638 | Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy. |
| Q89622483 | Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future |
| Q41891283 | Malignant intraperitoneal mesothelioma-Başkent University experience |
| Q80961479 | Malignant mesothelioma |
| Q21202901 | Malignant mesothelioma |
| Q37261327 | Malignant mesothelioma after household exposure to asbestos |
| Q37386569 | Malignant mesothelioma of the greater omentum mimicking omental infarction: a case report |
| Q41987896 | Malignant mesothelioma of the pericardium: a report of two different presentations |
| Q27311380 | Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review. |
| Q89924108 | Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature |
| Q47098675 | Malignant mesothelioma: Canadian perspective and research directions |
| Q37209613 | Malignant mesothelioma: current status and perspective in Japan and the world |
| Q36252181 | Malignant mesothelioma: current status of histopathologic diagnosis and molecular profile |
| Q28390539 | Malignant mesothelioma: facts, myths, and hypotheses |
| Q42203306 | Malignant paratesticular mesothelioma |
| Q39107162 | Malignant pericardial mesothelioma : A systematic review of current practice |
| Q35614129 | Malignant peritoneal mesothelioma without asbestos exposure: An ovarian cancer imitator |
| Q41386272 | Malignant peritoneal mesothelioma. Is there a new treatment? |
| Q33871582 | Malignant peritoneal mesothelioma: a review |
| Q58541846 | Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives |
| Q33909330 | Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis |
| Q50197656 | Malignant pleural fluid from mesothelioma has potent biological activities. |
| Q83412919 | Malignant pleural mesothelioma |
| Q83466825 | Malignant pleural mesothelioma |
| Q84107270 | Malignant pleural mesothelioma |
| Q79332820 | Malignant pleural mesothelioma in a 14-year-old boy with right aortic arch |
| Q36766690 | Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review. |
| Q51326575 | Malignant pleural mesothelioma in a patient with systemic sclerosis: the first report. |
| Q40041012 | Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data. |
| Q59274199 | Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q36639812 | Malignant pleural mesothelioma: a comprehensive review |
| Q34513958 | Malignant pleural mesothelioma: an update on diagnosis and treatment options |
| Q37217764 | Malignant pleural mesothelioma: current and future perspectives |
| Q36834027 | Malignant pleural mesothelioma: current concepts in treatment |
| Q37529848 | Malignant pleural mesothelioma: current treatments and emerging drugs. |
| Q46864339 | Malignant pleural mesothelioma: further options |
| Q26821919 | Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health |
| Q42362338 | Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient |
| Q36728254 | Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. |
| Q37866786 | Malignant pleural mesothelioma: when is radiation therapy indicated? |
| Q95360809 | Management of database: European Society of Thoracic Surgeons mesothelioma database-difficulties in improving quality data for rare tumour |
| Q31117531 | Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database |
| Q38215513 | Management of malignant pleural mesothelioma-The European experience |
| Q37277434 | Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). |
| Q35834928 | Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). |
| Q37621554 | Management of venous thromboembolism and the potential to impact overall survival in patients with cancer |
| Q36830116 | Management options for malignant pleural mesothelioma: clinical and cost considerations |
| Q51996240 | Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. |
| Q30437261 | Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso |
| Q39784143 | Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. |
| Q38542421 | Medical and oncological management of malignant mesothelioma. |
| Q52672887 | Medical treatment of malignant pleural mesothelioma relapses. |
| Q37866663 | Medical treatment of mesothelioma: anything new? |
| Q58132938 | Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma |
| Q33835620 | Membrane topological analysis of the proton-coupled folate transporter (PCFT-SLC46A1) by the substituted cysteine accessibility method |
| Q38971472 | Membranous nephropathy associated with malignant pleural mesothelioma in an adult patient: A case report |
| Q34193347 | Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship |
| Q61451037 | MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed |
| Q35885161 | Mesothelial cell proliferation and apoptosis |
| Q38773361 | Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy |
| Q60934613 | Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors |
| Q37201356 | Mesothelioma and asbestos-related pleural diseases |
| Q37381458 | Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival |
| Q45182633 | Mesothelioma research as a social issue |
| Q38476131 | Mesothelioma treatment |
| Q26800042 | Mesothelioma treatment: Are we on target? A review |
| Q92898853 | Mesothelioma: Hippo pathway as a target, lessons from COMMAND |
| Q35839385 | Mesothelioma: a review |
| Q81299291 | Mesothelioma: time to take stock |
| Q58122667 | Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells |
| Q36361245 | Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways |
| Q37562633 | Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma |
| Q47271729 | Micro-RNA149 Confers Taxane Resistance to Malignant Mesothelioma Cells via Regulation of P-glycoprotein Expression |
| Q47170177 | Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts—a case report |
| Q50585162 | Minute localized malignant pleural mesothelioma coexisting with multiple adenocarcinomas. |
| Q34040130 | Modeling the relationship between progression-free survival and overall survival: the phase II/III trial |
| Q29248127 | Modern management of malignant pleural mesothelioma |
| Q36699347 | Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability |
| Q37232301 | Molecular biology of malignant mesothelioma |
| Q38012566 | Molecular pathogenesis of malignant mesothelioma |
| Q38107102 | Molecular pathogenesis of malignant mesothelioma |
| Q79968444 | Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors |
| Q41869395 | Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease. |
| Q28482133 | Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma |
| Q36822118 | Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma |
| Q36097706 | Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma |
| Q43466291 | Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. |
| Q36599666 | Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent? |
| Q36889671 | Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma |
| Q50137415 | Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS. |
| Q88649792 | NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial |
| Q52564739 | Nano-selenium and its nanomedicine applications: a critical review. |
| Q40354488 | Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial |
| Q35958459 | Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors |
| Q52581757 | New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. |
| Q35042668 | New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials |
| Q87296127 | New directions in the second line treatment of non-small cell lung cancers and in the management of malignant pleural mesotheliomas |
| Q34101029 | New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells. |
| Q52672888 | New horizons from immunotherapy in malignant pleural mesothelioma. |
| Q26859274 | New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas |
| Q36157300 | New therapeutic options for mesothelioma |
| Q36780582 | Newer issues in mesothelioma chemotherapy. |
| Q34998586 | Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma |
| Q92134619 | Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial |
| Q91966584 | Nivo-lution in Mesothelioma |
| Q89411795 | Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes |
| Q99582736 | Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program |
| Q34364821 | Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma |
| Q40271615 | Nonparametric covariate adjustment in estimating hazard ratios |
| Q44551180 | Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. |
| Q39500865 | Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis |
| Q35594038 | Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived |
| Q39455555 | Novel insights into mesothelioma biology and implications for therapy. |
| Q33890499 | Novel systemic therapy against malignant pleural mesothelioma |
| Q37855667 | Novel targeted therapies and vaccination strategies for mesothelioma |
| Q52672324 | Novel therapies for malignant pleural mesothelioma. |
| Q35129535 | Novel therapies in phase II and III trials for malignant pleural mesothelioma. |
| Q40051845 | Oncolytic Viral Therapy for Mesothelioma |
| Q33402865 | Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy |
| Q38662242 | Optimal Therapy of Advanced Stage Mesothelioma |
| Q50484415 | Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study. |
| Q36905239 | Optimising survival in malignant mesothelioma |
| Q33710475 | Optimizing Collection of Adverse Event Data in Cancer Clinical Trials Supporting Supplemental Indications |
| Q26747641 | Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression |
| Q38826424 | Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model |
| Q50048236 | Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery |
| Q39643717 | Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma |
| Q34360248 | Overview of the biochemical and genetic processes in malignant mesothelioma. |
| Q47654312 | PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. |
| Q82257520 | PET-guided dose escalation tomotherapy in malignant pleural mesothelioma |
| Q37252398 | PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma |
| Q38398970 | PTEN protein expression in malignant pleural mesothelioma |
| Q64085851 | Pain management in patients with malignant mesothelioma: challenges and solutions |
| Q26768306 | Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: current clinical practice or misnomer? |
| Q39377749 | Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors |
| Q45327540 | Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia |
| Q41697761 | Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma |
| Q26750670 | Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review |
| Q40168311 | Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. |
| Q50168144 | Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. |
| Q33732386 | Pemetrexed alters folate phenotype and inflammatory profile in EA.hy 926 cells grown under low-folate conditions |
| Q87591998 | Pemetrexed ameliorates experimental arthritis in rats |
| Q34091240 | Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. |
| Q37388593 | Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. |
| Q48620677 | Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study |
| Q28081243 | Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review) |
| Q36166142 | Pemetrexed disodium |
| Q80890800 | Pemetrexed disodium |
| Q24243222 | Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma |
| Q34253505 | Pemetrexed disodium in ovarian cancer treatment |
| Q38251598 | Pemetrexed for ovarian cancer: a systematic review of the published literature and a consecutive series of patients treated in a nonclinical trial setting |
| Q38107552 | Pemetrexed for the treatment of non-small cell lung cancer. |
| Q35003631 | Pemetrexed for the treatment of non-small-cell lung cancer |
| Q34113895 | Pemetrexed in advanced non-small-cell lung cancer |
| Q44523490 | Pemetrexed in combination with cisplatin versus cisplatin monotherapy in East Asian patients with recurrent or metastatic head and neck cancer: Results of an exploratory subgroup analysis of a phase III trial |
| Q58828317 | Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer |
| Q37818301 | Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature |
| Q45799446 | Pemetrexed in patients with refractory soft tissue sarcoma: a non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005. |
| Q36817105 | Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial |
| Q34516941 | Pemetrexed in thoracic cancer |
| Q88200768 | Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage |
| Q33379936 | Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. |
| Q34401277 | Pemetrexed therapy for malignant pleural mesothelioma |
| Q34517532 | Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy |
| Q47134185 | Pemetrexed-Induced Interstitial Pneumonitis: A Case Study and Literature Review |
| Q36118385 | Pemetrexed-cisplatin combination in mesothelioma |
| Q39297327 | Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review |
| Q61811213 | Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study |
| Q38415044 | Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. |
| Q37492386 | Pericardial Effusion due to Primary Malignant Pericardial Mesothelioma: A Common Finding but an Uncommon Cause |
| Q55107856 | Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review. |
| Q36790055 | Perspective on malignant pleural mesothelioma diagnosis and treatment |
| Q50648690 | Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. |
| Q36600202 | Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature |
| Q37877715 | Pharmacokinetic evaluation of pemetrexed |
| Q38733577 | Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers |
| Q64890042 | Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer a |
| Q40951154 | Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas |
| Q33442594 | Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). |
| Q46781636 | Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium |
| Q37367634 | Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma |
| Q35931270 | Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer |
| Q35432484 | Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer |
| Q44405249 | Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma |
| Q92450953 | Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905) |
| Q34614847 | Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma |
| Q37212223 | Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group |
| Q35686880 | Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma |
| Q36337646 | Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509 |
| Q35840886 | Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report |
| Q40814215 | Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy |
| Q37081896 | Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma |
| Q33369094 | Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer |
| Q35677288 | Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17). |
| Q37126012 | Phase II study of pemetrexed in patients with advanced neuroendocrine tumors |
| Q34549793 | Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma |
| Q34877504 | Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. |
| Q53584625 | Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. |
| Q37439034 | Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma |
| Q34747440 | Photodynamic therapy for lung cancer and malignant pleural mesothelioma. |
| Q39779237 | Photodynamic therapy for malignant pleural mesothelioma: the future of treatment? |
| Q55605572 | Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo. |
| Q40166240 | Pleural Diseases: Saline Irrigation in Pleural Infection, Epidemiology of Pneumothorax, and Bevacizumab in Mesothelioma |
| Q37777879 | Pleural Malignancies |
| Q42582696 | Pleural effusion: what lies underneath? |
| Q35168185 | Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network |
| Q35903121 | Pleural mesothelioma: little evidence, still time to do trials |
| Q41429967 | Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes |
| Q33831942 | Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma |
| Q38905403 | Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection |
| Q37001982 | Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report |
| Q51444618 | Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil. |
| Q36287976 | Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies |
| Q39260316 | Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy |
| Q54949713 | Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane. |
| Q39463417 | Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin |
| Q50049398 | Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma |
| Q89838575 | Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer |
| Q53129830 | Primary malignant mesothelioma of the spermatic cord. |
| Q37406758 | Primary malignant pericardial mesothelioma with increased serum mesothelin diagnosed by surgical pericardial resection: A case report |
| Q93338919 | Product review: avelumab, an anti-PD-L1 antibody |
| Q38961442 | Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma |
| Q33918135 | Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey |
| Q43875251 | Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma |
| Q41234207 | Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis |
| Q53175010 | Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma. |
| Q89759390 | Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma |
| Q39124644 | Prognostication and monitoring of mesothelioma using biomarkers: a systematic review |
| Q51501402 | Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells. |
| Q52663125 | Progress in the Management of Malignant Pleural Mesothelioma in 2017. |
| Q89889132 | Prolonged Progression-Free Survival in a Patient With Malignant Pleural Mesothelioma Following Korean Herbal Medicine Treatment Alone: A Case Report |
| Q40223042 | Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients†. |
| Q95548086 | Prophylactic radiotherapy to prevent procedure-tract metastases |
| Q24170504 | Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells |
| Q47096168 | Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis |
| Q42825571 | Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene |
| Q37020881 | Protein kinase C beta in malignant pleural mesothelioma |
| Q36526737 | Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention |
| Q30614413 | Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases. |
| Q55037897 | Proton beam therapy for malignant pleural mesothelioma. |
| Q52560709 | Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma. |
| Q55082913 | Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study. |
| Q55318621 | Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma. |
| Q45020726 | Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. |
| Q47197708 | Radical multimodality therapy for malignant pleural mesothelioma. |
| Q39438176 | Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma |
| Q37392453 | Radiotherapy applications of patients with malignant mesothelioma: A single center experience |
| Q24245556 | Radiotherapy for malignant pleural mesothelioma |
| Q37945636 | Raltitrexed in mesothelioma |
| Q90659960 | Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol |
| Q52562413 | Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer. |
| Q33404434 | Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study |
| Q36425940 | Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma |
| Q34142500 | Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma |
| Q34402081 | Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. |
| Q44647820 | Re: a multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma |
| Q28392665 | Reactive oxygen species a double-edged sword for mesothelioma |
| Q49703405 | Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study. |
| Q34265773 | Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer |
| Q36779095 | Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation |
| Q91949964 | Relations between approved platinum drugs and non-coding RNAs in mesothelioma |
| Q30240233 | Relevance of randomised controlled trials in oncology. |
| Q35175013 | Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma |
| Q35567272 | Resistance to antifolates |
| Q42585963 | Response to comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'. |
| Q39073648 | Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. |
| Q43132169 | Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed |
| Q58128741 | Review of nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial |
| Q36822893 | Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma |
| Q37873380 | Review on clinical trials of targeted treatments in malignant mesothelioma |
| Q28066950 | Role of Akt signaling in resistance to DNA-targeted therapy |
| Q38190418 | Role of microRNAs in malignant mesothelioma. |
| Q39043688 | Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database |
| Q89753976 | Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma |
| Q39991261 | SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells |
| Q39359156 | SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma |
| Q39350876 | SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model |
| Q52802449 | SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. |
| Q38786021 | Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer |
| Q37478901 | Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade |
| Q89390949 | Scientific Advances and New Frontiers in Mesothelioma Therapeutics |
| Q38365768 | Searching for targets for the systemic therapy of mesothelioma. |
| Q33582141 | Second generation sequencing of the mesothelioma tumor genome |
| Q50665635 | Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. |
| Q42864235 | Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006) |
| Q37937879 | Second-line treatment options in advanced non-small cell lung cancer |
| Q33434963 | Seminiferous epithelium damage after short period of busulphan treatment in adult rats and vitamin B12 efficacy in the recovery of spermatogonial germ cells. |
| Q26828610 | Serine, glycine and one-carbon units: cancer metabolism in full circle |
| Q34687224 | Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma |
| Q36105547 | Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma |
| Q54678404 | Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. |
| Q26860736 | Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis |
| Q83017468 | Severe rhabdomyolysis associated with pemetrexed-based chemotherapy |
| Q48315996 | Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo. |
| Q59796596 | Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report |
| Q34543815 | Single agent and combination studies of pralatrexate and molecular correlates of sensitivity |
| Q46170046 | Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions |
| Q37582256 | Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review |
| Q34096881 | Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels |
| Q36858876 | Speeding up the evaluation of new agents in cancer |
| Q52990918 | Spontaneous Regression of Malignant Pleural Mesothelioma in a Patient with New-Onset Inflammatory Arthropathy. |
| Q33563281 | Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date |
| Q80218915 | Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase |
| Q46807402 | Standard therapy for the treatment of malignant pleural mesothelioma |
| Q99594750 | Standards of care in mesothelioma treatment |
| Q38204673 | Standing the test of time: targeting thymidylate biosynthesis in cancer therapy |
| Q34501203 | Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin |
| Q44080402 | Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis |
| Q44282851 | Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma |
| Q36451785 | Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells |
| Q37762833 | Surgery for malignant pleural mesothelioma |
| Q37552639 | Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position |
| Q37398672 | Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. |
| Q36594263 | Surgical controversies in mesothelioma: MesoVATS addresses the role of surgical debulking |
| Q38195607 | Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies. |
| Q51716124 | Surgical resection of mesothelioma: an evidence-free practice. |
| Q30401535 | Surgical treatment of malignant pleural mesothelioma |
| Q38163913 | Surgical treatment of peritoneal carcinomatosis: current treatment modalities |
| Q53184110 | Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. |
| Q40165996 | Survival improvement in thoracic cancer: progress from the last decade and beyond |
| Q38607308 | Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response |
| Q50286398 | Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors. |
| Q92958905 | Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid-Lipid Conjugate |
| Q42131424 | Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma |
| Q38765125 | Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model |
| Q49387613 | Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro |
| Q41279899 | Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists |
| Q34622818 | Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials |
| Q38131498 | Systematic review of trimodality therapy for patients with malignant pleural mesothelioma |
| Q93380858 | Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma |
| Q33834736 | Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma |
| Q38586323 | Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. |
| Q37260408 | Systemic treatments for mesothelioma: standard and novel |
| Q23910293 | TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages |
| Q85246015 | TS expression predicts postoperative recurrence in adenocarcinoma of the lung |
| Q43605106 | TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer |
| Q37620658 | TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer |
| Q52672891 | Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma. |
| Q33322420 | Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies |
| Q55247848 | Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications. |
| Q39438189 | Targeting eukaryotic protein translation in mesothelioma |
| Q47107902 | Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models |
| Q47133472 | Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma |
| Q52642770 | Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. |
| Q38815319 | Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma |
| Q47393402 | Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma |
| Q43800002 | Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study |
| Q47133389 | The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma |
| Q88516121 | The Antemortem Diagnosis of Primary Malignant Pericardial Mesothelioma: A Multidisciplinary Evaluation |
| Q38935092 | The MesoVATS trial: is there a future for video-assisted thoracoscopic surgery partial pleurectomy? |
| Q36753856 | The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma |
| Q89502927 | The Role of Neoadjuvant Chemotherapy in Patients with Resectable Malignant Pleural Mesothelioma - An Institutional and National Analysis |
| Q36101238 | The Role of Regulatory T Cells in Mesothelioma. |
| Q35274923 | The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication |
| Q37183495 | The antifolates |
| Q41376845 | The challenge of prognostic markers in pleural mesothelioma |
| Q34464981 | The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience. |
| Q38125259 | The current state of pemetrexed in ovarian cancer |
| Q35274986 | The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial. |
| Q35686558 | The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma |
| Q42019544 | The evolution of multimodality therapy for malignant pleural mesothelioma |
| Q28067111 | The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma |
| Q36671963 | The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma |
| Q38148036 | The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms |
| Q92134624 | The future of mesothelioma treatment: time to shift gear |
| Q51937381 | The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. |
| Q55339037 | The management of malignant pleural mesothelioma in the USA 2004-13-a decade of lost opportunity? |
| Q42995477 | The need for randomized trials in mesothelioma: let's walk the talk |
| Q33890518 | The promise of emerging developments and concepts in mesothelioma |
| Q33658554 | The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy |
| Q35200628 | The role of interleukin-6 in malignant mesothelioma |
| Q55432585 | The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review. |
| Q45952963 | The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. |
| Q39631400 | The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice |
| Q35051339 | Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma. |
| Q39290976 | Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma |
| Q64101494 | Therapeutic efficacy evaluation of radioimmunotherapy with Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma |
| Q44537561 | Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. |
| Q46601914 | Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma |
| Q51709284 | Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. |
| Q53641990 | Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma. |
| Q53657513 | Thromboembolic Events in Malignant Pleural Mesothelioma. |
| Q36696282 | Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma |
| Q37929783 | Thymidylate synthase inhibitors for non-small cell lung cancer |
| Q92067214 | Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial |
| Q37745215 | Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia. |
| Q57818345 | Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation |
| Q37806309 | Translational advances in pleural malignancies |
| Q42563176 | Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma |
| Q37734455 | Translational therapies for malignant pleural mesothelioma. |
| Q44681845 | Treatment and survival analyses of malignant mesothelioma in Japan |
| Q40341641 | Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma. |
| Q61583558 | Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future |
| Q36967160 | Treatment of acute lymphoblastic leukaemia : a new era. |
| Q55078906 | Treatment of malignant pleural mesothelioma: lessons learned and quo vadis? |
| Q39476907 | Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study |
| Q56892124 | Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study |
| Q44807139 | Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial |
| Q38631254 | Tremelimumab for the treatment of malignant mesothelioma |
| Q28209997 | Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol |
| Q46988434 | Triplet chemotherapy for malignant pericardial mesothelioma: a case report |
| Q35591904 | Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma. |
| Q37597672 | Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma |
| Q35880415 | Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma. |
| Q92460078 | Tumour Treating Fields for mesothelioma |
| Q92460083 | Tumour Treating Fields for mesothelioma |
| Q90808642 | Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial |
| Q101216977 | Tumour treating fields therapy for glioblastoma: current advances and future directions |
| Q36755500 | Update on the molecular biology of malignant mesothelioma |
| Q41220761 | Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma |
| Q53193985 | Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. |
| Q45226201 | Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. |
| Q36370311 | Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma |
| Q38758684 | Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials |
| Q34715788 | Validation of genomics-based prognostic tests in malignant pleural mesothelioma |
| Q28534042 | Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy |
| Q47965170 | Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. |
| Q37768280 | Vinflunine: review of a new vinca alkaloid and its potential role in oncology |
| Q35129531 | Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. |
| Q34541123 | Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression |
| Q46774434 | Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial |
| Q37731754 | WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. |
| Q37252039 | What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK. |
| Q33781142 | What's the place of immunotherapy in malignant mesothelioma treatments? |
| Q64100362 | When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All? |
| Q36946792 | Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. |
| Q33164204 | Wide complex ventricular tachycardia presenting sign of metastatic pleural mesothelioma |
| Q35172562 | Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma |
| Q41706958 | Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. |
| Q39404727 | YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. |
| Q39947427 | YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation |
| Q58694739 | Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial |
| Q34653709 | Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels |
| Q55444837 | [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer]. |
| Q84192226 | [Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion] |
| Q80197048 | [Diagnosis and treatment of pleural effusion] |
| Q82061962 | [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma] |
| Q80352930 | [Malignant pleural mesothelioma (2003 update)] |
| Q80426618 | [Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic] |
| Q80311660 | [Metastatic obstruction of the small bowel complicating malignant pleural mesothelioma] |
| Q86911325 | [Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg] |
| Q81415520 | [Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study] |
| Q80370987 | [Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer] |
| Q81012365 | [Spontaneous pneumothorax revealing malignant pleural mesothelioma. Three case reports] |
| Q89416570 | [Surgical therapy of malignant pleural mesothelioma] |
| Q99237750 | gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma |
| Q42412951 | microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma. |
| Q27678339 | Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets |
| Q21261297 | Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for |
Search more.